Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
    • AGM Invitations
    • IPOs
  • InderesTV
  • Forum
  • Discovery
  • Om os
    • Fulgte selskaber
    • Team

Du bruger tilsyneladende en bredere skærm. Vil du gerne give denne side en bredere visningsoplevelse?

Ascelia Pharma - Update on re-evaluation of Sparkle headline data

Af HC Andersen Capital
Ascelia Pharma

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma on 20 september 2023 at 10 AM.

Ascelia Pharma has now completed the plan for the required re-evaluation of SPARKLE images. In the new plan, headline results from SPARKLE are expected by May 2024.

Read full announcement here: https://www.ascelia.com/mfn_news/ascelia-pharma-to-reach-headline-results-from-sparkle-re-evaluation-by-may-2024-with-current-funding/.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 14-09-2023 3.23PM.

Seneste videoer

B&O - CEO-interview i forbindelse med Q3 2025/26 handelsopdateringen
16.04.2026, 15.47 Bang & Olufsen
Luotea: A turnaround case with strong cash flow
16.04.2026, 09.52 Luotea
Dustin Group, Audiocast, Q2'26
15.04.2026, 09.30 Dustin Group
HCA Morgenbørs 15/04 - Negative markeder og fokus på Tryg efter Q1
15.04.2026, 09.26 DFDS
HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig
14.04.2026, 09.25 Demant
Vis alle videoer
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.